Patient-derived Tumor
Patient-derived Tumor - Related Videos
03:56
Tumor Enzymatic Digestion: A Procedure to Generate Tumor Cell Suspension from Patient-derived Xenograft Cancer Mouse Models
0 Views •
2023
This video describes the procedure to obtain tumor cell suspension from patient-derived xenograft or PDX cancer mouse models. Small animal models provide an expeditious, reproducible, and adaptable platform to study tumor progression and different metastatic...
08:03
Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells
0 Views •
Cited by 59 •
2015
This manuscript details a method used to generate prostate cancer patient derived xenografts (PDXs) from circulating tumor cells (CTCs). The generation of PDX models from CTCs provides an alternative experimental model to study prostate cancer; the most commonly diagnosed tumor and a frequent cause of death from cancer in men.
09:29
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
0 Views •
Cited by 23 •
2016
Utilizing patient-derived tumors in a subcutaneous preclinical model is an excellent way to study the efficacy of novel therapies, predictive biomarker discovery, and drug resistant pathways. This model, in the drug development process, is essential in determining the fate of many novel anti-cancer therapies prior to clinical investigation.
07:44
Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
0 Views •
2025
The development of orthotopic pediatric brain tumor models requires meticulous precision, using a stereotaxic device to implant cancer cells precisely. The methodology presented here outlines the steps involved in preparing brain tumor cells, performing intracranial injections, and implementing a post-operative monitoring system to assess brain tumor engraftment.
09:53
Labeling of Breast Cancer Patient-derived Xenografts with Traceable Reporters for Tumor Growth and Metastasis Studies
0 Views •
Cited by 18 •
2016
We describe a method for stable labeling of patient-derived xenografts (PDXs) with lentiviral particles expressing green-fluorescent protein and luciferase reporters. This method allows for tracking the growth of PDXs at the primary site, as well as detecting spontaneous and experimental metastases using in vivo imaging systems.
FAQs
Careful processing can retain cellular and molecular characteristics from the original disease, allowing laboratory findings to remain connected to the patient’s tumor biology. This preservation supports genomic analysis, short-term culture, and development of patient-derived models. As a result, researchers can study disease features in a patient-specific context rather than relying only on generalized cancer systems.
Tumor heterogeneity means that cancer tissue can contain biologically distinct features within or between patient samples. Studying material directly from individuals helps investigators examine this variation and determine whether biomarkers or treatment responses are broadly relevant or limited to particular tumors. This context is important for interpreting experimental results and understanding why therapeutic responses may differ.
Genomic analysis examines molecular characteristics preserved in the clinical specimen and can help identify biomarkers associated with a patient’s disease. These findings provide a molecular basis for comparing tumors, investigating biologically relevant differences, and linking laboratory observations with clinical samples. In cancer research, such information supports studies of diagnosis, treatment response, and more personalized therapeutic strategies.
The process begins with tumor tissue obtained through biopsy or surgical resection. Researchers then process the specimen for an intended use, such as genomic analysis, short-term culture, or development of a patient-derived model. The resulting material is studied to connect tumor characteristics with biological findings, potential biomarkers, therapeutic responses, or resistance mechanisms.
Researchers may develop organoids or xenografts when they need a patient-derived model for investigating tumor biology or evaluating potential treatments. These models extend analysis beyond the original specimen while maintaining a connection to the individual’s disease. Their use can help compare experimental treatment responses and support research into patient-specific differences in cancer behavior.
Patient-derived tumors allow investigators to compare tumor characteristics with observed or experimentally evaluated treatment responses. By examining the same disease context through genomic analysis, culture, or patient-derived models, researchers can explore features associated with resistance. This approach supports cancer studies seeking biomarkers of response, explanations for treatment failure, and strategies better aligned with individual tumor biology.